US trial starts for stentless tissue valve:
This article was originally published in Clinica
Executive Summary
St Jude Medical has performed the first US implant of its next-generation stentless tissue valve, as part of an FDA approved trial. The Toronto Root bioprosthesis combines the firm's Toronto SPV valve with its BiLinx anticalfication technology, which St Jude claims is the only technology designed to reduce calcification on the aortic wall as well as on the aortic leaflets. The St Paul, Minnesota company recently began a limited market launch of the product in Europe.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.